Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

UMaine professor McGill receives top German research award

ORONO — University of Maine ecology professor Brian McGill was awarded the Humboldt Research Award, one of the most prestigious scientific...

20 July 2023

Four Maine workforce programs could get $6.5M in fed funding

Four workforce training programs in Maine could receive nearly $6.5 million in federal funding through the markup of the fiscal year 2024 financial...

18 July 2023

Music as medicine: FDA approves stroke damage therapy from Portland startup

Doctors may soon start writing an unconventional prescription to help stroke survivors regain their ability to walk: music. MedRhythms, a Portland...

14 July 2023